8-K: Monogram Technologies Declares Preferred Stock Dividend Payable in Kind

Monogram Technologies has announced a dividend of $0.0255 per share for its Series D Preferred Stock, payable in kind based on the company's common stock price.

Summary

• Monogram Technologies has declared a dividend of $0.0255 per share for holders of its 8.00% Series D Convertible Cumulative Preferred Stock.
• The dividend will be paid in kind, meaning shareholders will receive shares of common stock based on the closing price on September 30, 2024.
• The record date for the dividend is October 1, 2024, and the payment date is October 15, 2024.
• Dividends on the Series D Preferred Stock are payable quarterly, typically around the 15th of January, April, July, and October.

Sentiment

Score: 6

Explanation: The announcement is neutral to slightly positive, as it confirms the company's commitment to its preferred shareholders. However, the company's reliance on future capital raises and regulatory approvals tempers the positive sentiment.

Positives

• The declaration of a dividend may be seen as a positive sign for investors in the Series D Preferred Stock.
• Paying the dividend in kind could potentially increase the number of common shares outstanding, which may improve liquidity.

Risks

• The company's future performance is subject to risks, including its lack of profitability and need for additional capital.
• The company depends on partners for product development and faces uncertainties in obtaining regulatory approvals.
• The company is subject to litigation risks.

Future Outlook

The company is developing a product solution architecture to enable patient-optimized orthopedic implants at scale by combining 3D printing, advanced machine vision, AI and next-generation robotics. The company anticipates that there may be other clinical and commercial applications for its navigated mBs precision robot and mVision navigation.

Management Comments

• Monogram Technologies is focused on improving human health with an initial focus on orthopedic surgery.
• The company is developing a product solution architecture to enable patient-optimized orthopedic implants at scale.
• Monogram's mBs precision robotic surgical system is designed to autonomously execute optimized paths for high-precision insertion of its FDA-cleared mPress press-fit implants.

Industry Context

The announcement is relevant to the medical technology and robotics industries, particularly those focused on orthopedic surgery and AI-driven solutions. The company is positioning itself as a leader in personalized knee implants.

Comparison to Industry Standards

• Monogram Technologies is competing with companies like Stryker, Zimmer Biomet, and Medtronic in the orthopedic implant and surgical robotics market.
• The company's focus on AI and personalized implants is a differentiating factor compared to traditional orthopedic companies.
• The company's mBs precision robotic surgical system is designed to autonomously execute optimized paths for high-precision insertion of its FDA-cleared mPress press-fit implants, which is a similar approach to other robotic surgery companies such as Intuitive Surgical.

Stakeholder Impact

• Preferred shareholders will receive a dividend payment.
• Common shareholders may experience a slight dilution due to the in-kind dividend payment.
• The company's employees and customers may benefit from the continued development of its technology.

Next Steps

• The company will pay the dividend on October 15, 2024.
• The company will continue to pursue FDA clearance for its robotic products.
• The company will continue to develop and explore other clinical and commercial applications for its technology.

Key Dates

Keywords

dividends, preferred stock, common stock, in kind, Monogram Technologies, MGRM, orthopedic surgery, AI, robotics